PCI Biotech Holding (0JGL.L) Stock Analysis & AI Equity Report
PCI Biotech Holding (0JGL.L) overview
PCI Biotech Holding (0JGL.L) stock analysis and AI equity research. For the latest completed financial year, 2024, PCI Biotech Holding reported revenue of NOK 6.7m and operating profit of NOK -18.0m; the year-end share price was 1.19 GBP and market capitalisation was GBP 44.4m. PCI Biotech Holding is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get PCI Biotech Holding's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-12-12. Data will be refreshed during report generation.
About PCI Biotech Holding
PCI Biotech Holding ASA is a Norwegian biopharmaceutical company in liquidation that previously developed photochemical technology platforms for life sciences applications. Its work focused on photochemical lysis for viral vector manufacturing and photochemical internalisation for light-triggered intracellular drug delivery. The company has also evaluated other bioprocessing-related opportunities while winding down operations.
Generate the PCI Biotech Holding report
PCI Biotech Holding is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for PCI Biotech Holding and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.